Skip to search formSkip to main contentSkip to account menu

LY 288513

Known as: LY288513 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Cholecystokinin antagonists (part 1): Antinociceptive, anxiolytic and antidepressant effects of N-(5-methyl-3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-N'-phenylureas and carboxamides.
The SAR optimization of the pyrazoline template resulted in novel 3-oxo-1,2-diphenyl-2,3-dihydro-1H-pyrazol-4-yl)-indole… 
2000
2000
The Effect of a Cholecystokinin Agonist on Masseter Muscle Activity in the Cat
The CCKB agonist, pentagastrin, has been shown to induce anxiety in human subjects. Similarly, in the cat model, pentagastrin… 
1998
1998
Cholecystokinin B receptors in the periaqueductal gray potentiate defensive rage behavior elicited from the medial hypothalamus of the cat
1998
1998
[Behavioral and neurochemical study on the role of the brain cholecystokinin system in anxiety].
In order to elucidate the involvement of cholecystokinin (CCK) in the regulation of anxiety, the author examined the effects of… 
1997
1997
The novel atypical antipsychotic olanzapine, but not the CCK-B antagonist LY288513, blocks apomorphine-induced disruption of pre-pulse inhibition
1996
1996
Evaluation of the specificity and potency of a series of cholecystokinin-B/gastrin receptor antagonists in vivo.
The potency and specificity of five proposed cholecystokinin-B receptor antagonists, YM022, RP73870, L-740,093, L-365,260 and… 
1994
1994
The CCK‐B Antagonist LY288513 Blocks Diazepam‐Withdrawal‐Induced Increases in Auditory Startle Response
In humans, withdrawal from the chronic use of benzodiazepines can result in a variety of undesirable side effects, including… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)